Erratum: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: A phase II blinded randomized trial (Neuro Oncol (2021) 23:3 (478-486) DOI: 10.1093/neuonc/noaa193)

  • Wen Chi Yang
  • , Ya Fang Chen
  • , Chi Cheng Yang
  • , Pei Fang Wu
  • , Hsing Min Chan
  • , Jenny Ling Yu Chen
  • , Guann Yiing Chen
  • , Jason Chia Hsien Cheng
  • , Sung Hsin Kuo
  • , Feng Ming Hsu*
  • *Corresponding author for this work

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

In the originally published version of this manuscript, the affiliation 'Graduate Institute of Oncology (W-C.Y., J.C-H.C., S-H.K., F-M.H.) and Cancer Research Center (W-C.Y., J.C-H.C., S-H.K., F-M.H.)' was incomplete. It has now been updated as follows: 'Graduate Institute of Oncology (W-C.Y., J.C-H.C., S-H.K., F-M.H.) and Cancer Research Center (W-C.Y., J.C-H.C., S-H.K., F-M.H.), National Taiwan University College of Medicine, Taipei, Taiwan'. In addition, in Table 1, item Primary cancer of the HA-WBRT group, the number of "Others: 3.0% (33)", has been corrected to "Others: 3.0% (1)".

Original languageEnglish
Pages (from-to)2125
Number of pages1
JournalNeuro-Oncology
Volume23
Issue number12
DOIs
StatePublished - 01 12 2021

Bibliographical note

Publisher Copyright:
© 2021 Oxford University Press. All rights reserved.

Fingerprint

Dive into the research topics of 'Erratum: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: A phase II blinded randomized trial (Neuro Oncol (2021) 23:3 (478-486) DOI: 10.1093/neuonc/noaa193)'. Together they form a unique fingerprint.

Cite this